庄文卓，医学博士，www.优德88.cpm 基础医学与生物科学学院细胞生物学教授。近年来，一直从事淋巴系统肿瘤的发病机制和耐药机制的研究。依据多发性骨髓瘤患者基因表达和临床特点，结合生物信息学、生物统计学多学科交叉综合研究，揭示了长链非编码RNA在骨髓瘤耐药和间充质干细胞成骨中的作用及机制，发现了在分子水平为骨髓瘤提供诊断、药物反应和预后评估的标志物，对指导骨髓瘤个体化治疗和预后评估，提高骨髓瘤的精准医疗水平有理论和实用双重意义。相关成果发表在Blood. 2021,Clin Cancer Res.2019;Oncogene.2018;Stem Cells.2018等杂志上。
1. 淋巴系统肿瘤非编码RNA表观遗传学研究。
2. 淋巴系统肿瘤药物的分子靶点及药物协同作用研究。
3. 探寻淋巴系统肿瘤分层诊断、预后评估的分子标志物，为实现淋巴系统肿瘤的个体化诊断和精准治疗提供策略。
以第一或通讯作者发表文章：
1.Han H, Fan G, Song S, Jiang Y, Qian C, Zhang W, Su Q, Xue X,Zhuang W (corresponding author), Li B. piRNA-30473 contributes to tumorigenesis and poor prognosis by regulating m6A RNA methylation in DLBCL.Blood. 2021 Mar 25;137(12):1603-1614.
2.Song S, Fan G, Li Q, Su Q, Zhang X, Xue X, Wang Z, Qian C, Jin Z, Li B,Zhuang W (corresponding author). IDH2 contributes to tumorigenesis and poor prognosis by regulating m6A RNA methylation in multiple myeloma.Oncogene. 2021 Sep;40(35):5393-5402.
3.Song S, Zhang J, Su Q, Zhang W, Jiang Y, Fan G, Qian C, Li B, Zhuang W(corresponding co-author). Downregulation of ITGA6 confers to the invasion of multiple myeloma and promotes progression to plasma cell leukaemia.Br J Cancer.2021 May;124(11):1843-1853.
4.Xu H, Han H, Song S, Yi N, Qian C, Qiu Y, Zhou W, Hong Y, Zhuang W, Li Z, Li B,Zhuang W(corresponding author).Exosome-Transmitted PSMA3 and PSMA3-AS1 Promotes Proteasome Inhibitors Resistance in Multiple Myeloma.Clin Cancer Res.2019 Mar 15;25(6):1923-1935.
5.Li B, Xu H, Han H, Song S, Zhang X, Ouyang L, Qian C, Hong Y, Qiu Y, Zhou W, Huang M*,Zhuang W*. Exosome-Mediated Transfer of lncRUNX2-AS1 from Multiple Myeloma Cells to MSCs Contributes to Osteogenesis.Oncogene.2018 Oct;37(41):5508-5519.
6.Li B, Han H, Song S, Fan G, Xu H, Zhou W, Qiu Y, Qian C, Wang Y, Yuan Z, Zhang Y*,Zhuang W*.HOXC10 Regulates Osteogenesis of Mesenchymal Stromal Cells through Interaction with its Natural Antisense Transcript lncHOXC-AS3.Stem Cells.2019 Feb;37(2):247-256.
7.Gu J, Song S, Han H, Xu H, Fan G, Qian C, Qiu Y, Zhou W,Zhuang W*, Li B*.The BET Bromodomain Inhibitor OTX015 Synergizes with Targeted Agents in Multiple Myeloma.Mol Pharm. 2018 Nov 5;15(11):5387-5396.
8.Shi J, Song S, Han H, Xu H, Huang M, Qian C, Zhang X, Ouyang L, Hong Y,Zhuang W*, Li B*. Potent Activity of the Bromodomain Inhibitor OTX015 in Multiple Myeloma.Mol Pharm.2018 Sep4;15(9):4139-4147.
9.Zhang X, Li B, Han H, Song S, Xu H, Yi Z, Hong Y,Zhuang W*, Yi N*. Pathway-Structured Predictive Modeling for Multi-Level Drug Response in Multiple Myeloma.Bioinformatics. 2018 Nov 1;34(21):3609-3615.
10.Zhang X, Li B, Han H, Song S, Xu H, Hong Y, Yi N*,Zhuang W*. Predicting Multi-Level Drug Response with Gene Expression Profile in Multiple Myeloma Using Hierarchical Ordinal Regression.BMC Cancer. 2018 May 10;18(1):551.
11.Zhuang W, Ge X, Yang S, Huang M, Zhuang W, Chen P, Zhang X, Qu J, Li B*.Upregulation of lncRNA MEG3 Promotes Osteogenic Differentiation of Mesenchymal Stem Cells from Multiple Myeloma Patients by Targeting BMP4 Transcription.Stem Cells. 2015 Jun;33(6):1985-97.
12.Li B, Chen P, Qu J, Shi L, Zhuang W, Fu J, Li J, Zhang X, Sun Y,Zhuang W*. Activation of LTBP3 Gene by a Long Noncoding RNA (lncRNA) MALAT1 Transcript in Mesenchymal Stem cells from Multiple Myeloma.J Biol Chem. 2014 Oct 17;289(42):29365-75.
庄文卓，医学博士，www.优德88.cpm 基础医学与生物科学学院细胞生物学教授。近年来，一直从事淋巴系统肿瘤的发病机制和耐药机制的研究。依据多发性骨髓瘤患者基因表达和临床特点，结合生物信息学、生物统计学多学科交叉综合研究，揭示了长链非编码RNA在骨髓瘤耐药和间充质干细胞成骨中的作用及机制，发现了在分子水平为骨髓瘤提供诊断、药物反应和预后评估的标志物，对指导骨髓瘤个体化治疗和预后评估，提高骨髓瘤的精准医疗水平有理论和实用双重意义。相关成果发表在Blood. 2021,Clin Cancer Res.2019;Oncogene.2018;Stem Cells.2018等杂志上。
1. 淋巴系统肿瘤非编码RNA表观遗传学研究。
2. 淋巴系统肿瘤药物的分子靶点及药物协同作用研究。
3. 探寻淋巴系统肿瘤分层诊断、预后评估的分子标志物，为实现淋巴系统肿瘤的个体化诊断和精准治疗提供策略。
以第一或通讯作者发表文章：
1.Han H, Fan G, Song S, Jiang Y, Qian C, Zhang W, Su Q, Xue X,Zhuang W (corresponding author), Li B. piRNA-30473 contributes to tumorigenesis and poor prognosis by regulating m6A RNA methylation in DLBCL.Blood. 2021 Mar 25;137(12):1603-1614.
2.Song S, Fan G, Li Q, Su Q, Zhang X, Xue X, Wang Z, Qian C, Jin Z, Li B,Zhuang W (corresponding author). IDH2 contributes to tumorigenesis and poor prognosis by regulating m6A RNA methylation in multiple myeloma.Oncogene. 2021 Sep;40(35):5393-5402.
3.Song S, Zhang J, Su Q, Zhang W, Jiang Y, Fan G, Qian C, Li B, Zhuang W(corresponding co-author). Downregulation of ITGA6 confers to the invasion of multiple myeloma and promotes progression to plasma cell leukaemia.Br J Cancer.2021 May;124(11):1843-1853.
4.Xu H, Han H, Song S, Yi N, Qian C, Qiu Y, Zhou W, Hong Y, Zhuang W, Li Z, Li B,Zhuang W(corresponding author).Exosome-Transmitted PSMA3 and PSMA3-AS1 Promotes Proteasome Inhibitors Resistance in Multiple Myeloma.Clin Cancer Res.2019 Mar 15;25(6):1923-1935.
5.Li B, Xu H, Han H, Song S, Zhang X, Ouyang L, Qian C, Hong Y, Qiu Y, Zhou W, Huang M*,Zhuang W*. Exosome-Mediated Transfer of lncRUNX2-AS1 from Multiple Myeloma Cells to MSCs Contributes to Osteogenesis.Oncogene.2018 Oct;37(41):5508-5519.
6.Li B, Han H, Song S, Fan G, Xu H, Zhou W, Qiu Y, Qian C, Wang Y, Yuan Z, Zhang Y*,Zhuang W*.HOXC10 Regulates Osteogenesis of Mesenchymal Stromal Cells through Interaction with its Natural Antisense Transcript lncHOXC-AS3.Stem Cells.2019 Feb;37(2):247-256.
7.Gu J, Song S, Han H, Xu H, Fan G, Qian C, Qiu Y, Zhou W,Zhuang W*, Li B*.The BET Bromodomain Inhibitor OTX015 Synergizes with Targeted Agents in Multiple Myeloma.Mol Pharm. 2018 Nov 5;15(11):5387-5396.
8.Shi J, Song S, Han H, Xu H, Huang M, Qian C, Zhang X, Ouyang L, Hong Y,Zhuang W*, Li B*. Potent Activity of the Bromodomain Inhibitor OTX015 in Multiple Myeloma.Mol Pharm.2018 Sep4;15(9):4139-4147.
9.Zhang X, Li B, Han H, Song S, Xu H, Yi Z, Hong Y,Zhuang W*, Yi N*. Pathway-Structured Predictive Modeling for Multi-Level Drug Response in Multiple Myeloma.Bioinformatics. 2018 Nov 1;34(21):3609-3615.
10.Zhang X, Li B, Han H, Song S, Xu H, Hong Y, Yi N*,Zhuang W*. Predicting Multi-Level Drug Response with Gene Expression Profile in Multiple Myeloma Using Hierarchical Ordinal Regression.BMC Cancer. 2018 May 10;18(1):551.
11.Zhuang W, Ge X, Yang S, Huang M, Zhuang W, Chen P, Zhang X, Qu J, Li B*.Upregulation of lncRNA MEG3 Promotes Osteogenic Differentiation of Mesenchymal Stem Cells from Multiple Myeloma Patients by Targeting BMP4 Transcription.Stem Cells. 2015 Jun;33(6):1985-97.
12.Li B, Chen P, Qu J, Shi L, Zhuang W, Fu J, Li J, Zhang X, Sun Y,Zhuang W*. Activation of LTBP3 Gene by a Long Noncoding RNA (lncRNA) MALAT1 Transcript in Mesenchymal Stem cells from Multiple Myeloma.J Biol Chem. 2014 Oct 17;289(42):29365-75.